OpenScience.ink

1 week ago • European journal of clinical pharmacology

Effectiveness and safety of GLP-1 drugs for weight gain and metabolism problems linked to antipsychotic useEfficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis.

📖 Top 20% JournalSystematic Review

1 week ago • Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

Safety and effectiveness of combining GLP-1 drugs with weight-loss surgery for obesity, based on treatment timing[Efficacy and safety of GLP-1 receptor agonists combined with bariatric surgery for obesity: a timing-stratified systematic review].

Systematic Review

3 weeks ago • Annals of cardiac anaesthesia

GLP-1 Receptor Agonists with Insulin Compared to Insulin Alone for Blood Sugar Control Around Heart Surgery in Type 2 DiabetesGLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic Review.

Systematic Review

1 week ago • Journal of clinical medicine

Mazdutide's effectiveness in treating GSD IXc: A case reportEffectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report.

📖 Top 20% JournalCase Reports

2 weeks ago • JAMA psychiatry

Patient-Reported Changes in Alcohol Use After Starting GLP-1 MedicationPatient-Reported Changes in Alcohol Use Following Glucagon-Like Peptide-1 Receptor Agonist Initiation.

🥇 Top 1% JournalArticle

3 weeks ago • Journal of agricultural and food chemistry

Short-Chain Fatty Acids May Slow DPP-IV Enzyme to Help Keep GLP-1 Stable and Support Metabolic HealthShort-Chain Fatty Acids as Endogenous Inhibitors of DPP-IV Enzyme: Implications in GLP-1 Stability and Metabolic Health.

📖 Top 20% JournalArticle

3 weeks ago • JAMA network open

How New Oral Semaglutide is Being Used and Spread Among US Adults with ObesityEarly Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity.

🥈 Top 2% JournalArticle

3 weeks ago • Alzheimer's & dementia : the journal of the Alzheimer's Association

Genetic evidence suggests activating brain GLP-1 receptors may protect thinking areas in Alzheimer's diseaseGenetic evidence supports a cortical neuroprotective role of GLP-1 receptor activation in Alzheimer's disease: A drug-target Mendelian randomization study.

🥈 Top 2% JournalArticle

1 week ago • Frontiers in drug safety and regulation

Panic Attacks After Tirzepatide Injection in Two Women with Recurrent DepressionCase Report: Panic attacks after tirzepatide injection in two female patients with recurrent depressive disorder.

📖 Top 50% JournalCase Reports

3 days ago • The AAPS journal

Using Charcoal to Reduce Drug Interference in Antibody Tests for Therapeutic PeptidesCharcoal-Based Depletion Method to Improve Drug Tolerance in Neutralizing Antibody Assays for Therapeutic Peptides.

🎖️ Top 10% JournalArticle

3 days ago • Frontiers in pharmacology

Pregnancy and birth outcomes after using GLP-1 and combined GLP-1/GIP receptor drugs during different timesPregnancy and perinatal outcomes following exposure to GLP-1 and dual GLP-1/GIP receptor agonists: a time-window-stratified systematic review and meta-analysis.

📖 Top 20% JournalArticle

3 days ago • Frontiers in endocrinology

Heart and kidney benefits of GLP-1 and dual GIP/GLP-1 receptor drugs beyond blood sugar controlBeyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.

🎖️ Top 10% JournalArticle

4 days ago • Frontiers in pharmacology

GLP-1 drugs and DPP-4 inhibitors linked to memory loss in older adults with type 2 diabetesExploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort.

📖 Top 20% JournalArticle

6 days ago • Frontiers in pharmacology

Using dual and triple-target drugs as new treatments for fatty liver disease linked to metabolism problemsFrom pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.

📖 Top 20% JournalArticle

6 days ago • Frontiers in pharmacology

Molecular insights into how GLP-1 receptor drugs work in type 2 diabetes and obesityInsights from multi-omics on GLP-1 receptor agonists in type 2 diabetes and obesity.

📖 Top 20% JournalArticle

1 week ago • Chemical communications (Cambridge, England)

Changing GLP-1’s shape prevents its breakdown while keeping its metal-binding partStereochemical engineering of GLP-1 blocks proteolysis while preserving its metal-binding core.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Using GLP-1 Treatments to Lower Heart Disease Risk in Kazakhstan: Evidence, Cost, Fair Access, and Practical IssuesGLP-1-Based Therapies for Cardiovascular Risk Reduction in Kazakhstan: Evidence, Affordability, Equity and Implementation Considerations.

📖 Top 20% JournalArticle

1 week ago • Antioxidants (Basel, Switzerland)

GLP-1’s role in controlling oxidative signals in metabolism and related diseasesGLP-1 as a Regulator of Oxidative Signalling in Metabolic Health and Disease.

🎖️ Top 10% JournalArticle

1 week ago • Life (Basel, Switzerland)

Fatty Liver Disease Linked to Metabolic Problems and Heart Risk: New Treatment Approaches Connecting Liver and Heart HealthMetabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease.

📖 Top 30% JournalArticle

1 week ago • International journal of molecular sciences

Targeting multiple pathways beyond single GLP-1 drugs for precise treatment and lasting change in childhood obesityPrecision Pharmacotherapy for Childhood Obesity: Molecular Targets Beyond Single GLP-1 Receptor Agonism and a Framework for Disease Modification.

📖 Top 20% JournalArticle

1 week ago • Nutrients

How Gut Bacteria and Inflammation May Affect Appetite and Eating Behavior in ObesityThe Microbiota-Gut-Brain Axis in Obesity: Inflammation, Appetite Dysregulation, and Feeding Behavior.

🎖️ Top 10% JournalArticle

1 week ago • Journal of clinical medicine

Semaglutide use in people with obesity and psoriasis over 18 months in real-life settingsSemaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Bile Duct and Pancreas Safety of Incretin-Based Treatments in Obesity and Type 2 Diabetes Compared Between Tirzepatide, Semaglutide, and DPP-4 InhibitorsBiliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Urinary Stone Return After Starting GLP-1 Therapy: A Romanian Study of Health, Kidney, and Hydration FactorsUrinary Stone Recurrence After Initiation of GLP-1-Based Therapy: A Romanian Retrospective Cohort Study of Clinical, Renal, and Hydration-Related Factors.

📖 Top 20% JournalArticle

1 week ago • International journal of molecular sciences

6-Gingerol boosts insulin release from insulin-producing cells without increasing gut hormone secretion6-Gingerol Potentiates β-Cell Insulin Secretion Without Acting as an L-Cell GLP-1 Secretagogue.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Effectiveness, side effects, and treatment adherence of Semaglutide and Liraglutide in Omani patientsReal-World Effectiveness, Documented Adverse Events, and Treatment Adherence of Semaglutide and Liraglutide in Omani Patients: A Retrospective Observational Study.

📖 Top 20% JournalArticle

1 week ago • Pharmaceuticals (Basel, Switzerland)

Comparing how well people with type 2 diabetes stick to and keep taking SGLT-2 inhibitors versus GLP-1 receptor agonists, especially in those with heart diseaseSGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study Comparing Adherence and Persistence with Specific Reference to Cardiovascular Disease.

📖 Top 20% JournalArticle

1 week ago • Frontiers in endocrinology

Semaglutide's effectiveness for obesity varies between patients with and without food cravingsA retrospective real-world study on semaglutide effectiveness in patients with obesity: differences between patients with and without food craving.

🎖️ Top 10% JournalArticle

1 week ago • Pharmaceutics

Advances in How Anti-Obesity Drugs Work in the BodyProgress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.

📖 Top 20% JournalArticle

1 week ago • Pharmaceutics

Retatrutide as a Single Drug Activating Three Hormone Receptors: Design, Development, and Review of New Phase 3 ResultsRetatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.

📖 Top 20% JournalArticle

← prevpage 2 of 16next →

GLP-1 Therapies Research Papers